ERIN WILKES: Open Payments
NPI 1306150412 · SANDERSVILLE, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,499 in 61 payments from 11 companies in 2025. Trend: 2023 $892 · 2024 $760 · 2025 $1,499
Food & beverage: $1,382Education: $117
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 14 | $332 |
| Janssen Pharmaceuticals, Inc | 9 | $232 |
| Vanda Pharmaceuticals Inc. | 4 | $209 |
| E.R. Squibb & Sons, L.L.C. | 7 | $190 |
| Alkermes, Inc. | 11 | $171 |
| Neurocrine BioSciences, Inc. | 6 | $141 |
| ABBVIE INC. | 4 | $88 |
| Supernus Pharmaceuticals, Inc. | 3 | $49 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $28 |
Products named: INVEGA SUSTENNA, FANAPT, AUSTEDO XR, COBENFY, ARISTADA, INGREZZA, VRAYLAR, Qelbree.
Industry payments across GA — which companies pay providers there.
